We hereby submitting the Unaudited Standalone & Consolidated Financial Results for the quarter ended 30.06.2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
ANG Lifesciences India Ltd reported Q1 FY26 results with strong top-line growth. Standalone revenue from operations rose to Rs 2,453.18 lakhs, up about 52% from Rs 1,617.67 lakhs in Q1 FY25. Total expenses increased to Rs 2,573.19 lakhs, keeping the standalone loss before tax at Rs 102.67 lakhs and loss for the period at Rs 78.73 lakhs (vs Rs 276.53 lakhs loss a year ago). On a consolidated basis (including subsidiary Mansa Print & Publishers Ltd), revenue was Rs 2,460.36 lakhs and the consolidated loss narrowed modestly to Rs 200.62 lakhs from Rs 307.30 lakhs in Q1 FY25. Statutory auditors Khurana Sharma & Co. issued an unmodified (clean) review report. Full-year FY25 standalone revenue stood at Rs 8,991.01 lakhs with a loss of Rs 1,034.29 lakhs, showing the company is still loss-making on an annual basis.
Strong revenue growth is a positive sign, but the company remains loss-making both for the quarter and the full year, which may keep the stock under pressure. The narrowing standalone loss and clean auditor opinion provide some comfort, but shareholders should watch for sustained profitability before turning constructive.